CTTQ
Status and phase
Conditions
Treatments
About
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
184 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
YuanKai Shi, Master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal